ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
2.145
-0.065 (-2.94%)
Mar 9, 2026, 4:00 PM EDT - Market closed
ALX Oncology Holdings Employees
ALX Oncology Holdings had 80 employees as of December 31, 2024. The number of employees increased by 8 or 11.11% compared to the previous year.
Employees
80
Change (1Y)
8
Growth (1Y)
11.11%
Revenue / Employee
n/a
Profits / Employee
-$2,311,250
Market Cap
281.42M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 80 | 8 | 11.11% |
| Dec 31, 2023 | 72 | 14 | 24.14% |
| Dec 31, 2022 | 58 | 15 | 34.88% |
| Dec 31, 2021 | 43 | 20 | 86.96% |
| Dec 31, 2020 | 23 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Puma Biotechnology | 179 |
| AC Immune | 172 |
| Coherus Oncology | 158 |
| Cabaletta Bio | 151 |
| Silence Therapeutics | 116 |
| OmniAb | 114 |
| C4 Therapeutics | 110 |
| Enlivex | 71 |
ALXO News
- 10 days ago - ALX Oncology Holdings Inc. (ALXO) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 18 days ago - ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026 - GlobeNewsWire
- 18 days ago - ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 - GlobeNewsWire
- 5 weeks ago - ALX Oncology Announces Pricing of Underwritten Offering - GlobeNewsWire
- 5 weeks ago - New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer - GlobeNewsWire
- 7 weeks ago - ALX Oncology Holdings Inc. (ALXO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire